Meet With Venture Capitalists, Raise Money for the LLS

If you think you're sitting on the idea of a lifetime but you lack the huge seed money to make it happen, believe it or not there are some Silicon Valley venture capitalists with deep pockets who are waiting to hear your idea. All you have to do is bid on their time, and win, with the money going to benefit the Leukemia & Lymphoma Society (LLS).

Motion To Dismiss Cancer is the name of a team created to raise money for the LLS, and one of the ways they do this is through their "Venture Capital Master's Lunch Series" auctions.

The highest bidders win face time with Silicon Valley venture caps, with whom they can get advice or pitch ideas. The list of influential men and women up for bid between 7 May and 17 May features some heavy hitters in the industry, including executives from Greylock Partners, Y Combinator, Draper Fisher Jurvetson, New Enterprise Associates, North Bridge Venture Partners, Bessemer Venture Partners, 23andMe, and RockHealth.

Since there are several lunch hour auctions per company, the bids are much lower than many might imagine, and either way the bids benefit the LLS.

Click this link to see the current auctions.

Click this one to learn more about Motion To Dismiss Cancer.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap